SynRx Therapeutics

E-mail

提交

Security Code

Refresh the code

Cancel

Confirm

Developing first-in-class medicines

Using synthetic lethality strategy, SynRx Therapeutics is developing novel anti-cancer agents. Several first-in-class compounds are currently in preclinical studies.

Founder

Xiaochun Yu

Professor, Founder and Chairman

Professor, University of Michigan Medical School
M.D., Beijing Medical University
Ph.D., Kurume University, Japan
Published more than 100 academic papers

SY001

SY001 focuses on an undisclosed target X, a critical enzyme in DNA damage repair. The expression of X is scarce in normal cells, while is overexpressed in tumor cells. X shows synthetic lethality with BRCA1/2 mutations or homologous recombination defects.

SY002

Genomic instability is a hallmark of cancer cells, which is largely caused by DNA damage repair defects. Targeting DNA damage repair pathways increases additional burdens to cancer cells and induces cancer cell lethality. This precision targeting strategy is called synthetic lethality.

News
Focus on the development of novel drugs targeting the DNA damage repair pathway

ADDRESS

8 The Green, Suite A
Dover, Delaware 19901.

ADDRESS

8 The Green,Suite A Dover,Delaware 19901.

CONTACT

E-mail：bd@synrx-therapeutics.com
hr@synrx-therapeutics.com

CONTACT

E-mail：bd@synrx-therapeutics.com
hr@synrx-therapeutics.com

SITEMAP